Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Current Deferred Revenue (2016 - 2025)

iBio (IBIO) has disclosed Current Deferred Revenue for 10 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 91.67% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 91.67% year-over-year, with the annual reading at $1.2 million for FY2025, 500.0% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $1.2 million at iBio, roughly flat from $1.2 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $1.2 million in Q2 2025, with the low at $8000.0 in Q1 2022.
  • Average Current Deferred Revenue over 4 years is $455937.5, with a median of $300000.0 recorded in 2024.
  • The sharpest move saw Current Deferred Revenue plummeted 99.1% in 2022, then soared 500.0% in 2025.
  • Over 4 years, Current Deferred Revenue stood at $60000.0 in 2021, then surged by 46.67% to $88000.0 in 2022, then skyrocketed by 581.82% to $600000.0 in 2024, then soared by 91.67% to $1.2 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $1.2 million, $1.2 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.